Albireo to Participate at Upcoming Investor Conferences
June 02, 2022 16:30 ET
|
Albireo Pharma, Inc.
BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022
May 23, 2022 08:30 ET
|
Albireo Pharma, Inc.
– Six abstracts presented highlighting data on BylvayTM (odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters – Pre-clinical study of systemic ASBT/NTCP inhibitors,...
Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022
May 19, 2022 16:30 ET
|
Albireo Pharma, Inc.
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright...
Albireo Reports Q1 2022 Financial Results and Business Update
May 16, 2022 16:01 ET
|
Albireo Pharma, Inc.
Positive Bylvay™ (odevixibat) global commercial launch in U.S., Germany and United Kingdom with Q1 2022 product revenue, net $4.7 million Phase 3 ASSERT study in Alagille syndrome fully enrolled,...
Albireo to Report Q1 2022 Financial Results on May 16
May 09, 2022 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome
March 29, 2022 08:30 ET
|
Albireo Pharma, Inc.
– Phase 3 ASSERT study on track to report topline data by the end of year – Albireo launches Expanded Access Program (EAP) for Alagille syndrome patients BOSTON, March 29, 2022 (GLOBE NEWSWIRE) --...
Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update
March 01, 2022 08:30 ET
|
Albireo Pharma, Inc.
Bylvay™ (odevixibat) launched in the U.S. and Europe, 2021 product revenue, net $7 millionNICE endorses clinical and economic benefits of BylvayPhase 3 study in Alagille syndrome on track for readout...
Albireo to Report Q4 and Year-End 2021 Financial Results on March 1
February 22, 2022 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
NICE Recommends Albireo’s Bylvay® (odevixibat) for All PFIC Types
February 22, 2022 07:00 ET
|
Albireo Pharma, Inc.
– Decision provides access to the first drug treatment approved in PFIC for patients in England, Wales and Northern Ireland – Positive NICE review completed in less than six months post MHRA approval...
Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease
February 14, 2022 08:30 ET
|
Albireo Pharma, Inc.
PFIC caregivers reported high impact on mental and physical health, productivity, career prospects, sleep, relationships and financesStudy suggests PFIC caregivers’ quality of life may be comparable...